Radiation Boosts DCIS Relapse-Free Survival in Women with Breast Cancer
BERN, Switzerland - Young women who have radiotherapy following surgery for ductal carcinoma in-situ (DCIS) are significantly less likely to have local recurrence and the risk was even lower when boost radiotherapy was added.
BERN, Switzerland, July 6 ? Radiotherapy following surgery for ductal carcinoma in-situ (DCIS) leads to a significantly lower risk of local recurrence, and the risk was even lower when boost radiotherapy was added.
Forty-six percent of young women who had surgical excision alone were relapse-free for 10 years, Aurelius Omlin, M.D., of the University of Bern, and colleagues, reported in Lancet Oncology, which was published online today.
But that rate jumped to 72% with radiation and to 86% for young women who had radiotherapy and an extra "boost" of radiation, said Dr. Bern and colleagues from 18 institutions in the United States and Europe.
The 10-year overall survival was 97% for all young women with no significant differences between the three treatment groups (P=0.96).
The authors pointed out that mammography screening has increased the number of DCIS diagnoses but "little is known about the best treatment in young patients with DCIS, who are a minority of the DCIS patients."
The investigators reviewed data from 373 women ages 45 or younger who were treated for DCIS from February 1978 through August 2004. Fifty-seven women had no radiation, 166 had surgery plus radiation (median dose 50 Gy), and 150 women had radiotherapy with boost (median dose 60 Gy).
"Compared with no radiotherapy, radiotherapy without boost was associated with a reduced risk of local relapse (P=0.004), as was radiotherapy with boost (P
3 Reasons Urology Practices Should Add Onsite UTI PCR Labs Under New LCD Rules
March 11th 20251. ONSITE PCR TESTING BRINGS SIGNIFICANT CLINICAL BENEFITS TO A PRACTICE. - ACCURACY Traditional urine cultures can give false-negative results. - SPECIFICITY Accurate microbial identification leads to targeted treatment. - SPEED Same day results vs. 3-5 days for traditional urine cultures - - - ANTIBIOTIC RESISTANCE MARKERS Improves antimicrobial stewardship 2. MAINTAIN INDEPENDENCE BY INCREASING REVENUE SIGNIFICANTLY THROUGH REVENUE SHIFTING FROM THE REFERENCE LAB TO THE PRACTICE. - Turnkey: Consultation on COLA and CLIA certification, all necessary equipment, standard operating procedures, personnel sourcing and interview, billing and coding training, 3-4 days of onsite training. - Stark Law Compliant: Complies with anti-kickback statutes. - Medicare part B pays at 100%, Med Advantage Plans at 80% - No lab build-out, only 8 linear feet of counter space needed - Z-code procurement for required states 3. BETTER PATIENT CARE LEADS TO BETTER OUTCOMES. - CONVENIENCE Point of care, no third-party referral lab. - TIMELY Results early in the care process. - CORRECT MEDICATION Avoids two trips to the pharmacy. - BETTER OUTCOMES Reduction of recurrent UTI and hospitalizations
